Aratana Therapeutics Inc. (NASDAQ:PETX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday. The firm currently has a $9.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research’s target price points to a potential upside of 18.11% from the stock’s previous close.

According to Zacks, “Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. “

PETX has been the subject of several other research reports. Jefferies Group started coverage on shares of Aratana Therapeutics in a research note on Friday, August 19th. They set a “buy” rating and a $13.00 price target for the company. Lake Street Capital restated a “buy” rating and set a $15.00 price target on shares of Aratana Therapeutics in a research note on Tuesday, September 6th. Barclays PLC decreased their price target on shares of Aratana Therapeutics from $15.00 to $11.00 and set an “overweight” rating for the company in a research note on Thursday, August 11th. William Blair restated an “outperform” rating on shares of Aratana Therapeutics in a research note on Wednesday, August 17th. Finally, Credit Suisse Group AG restated a “buy” rating and set a $11.00 price target on shares of Aratana Therapeutics in a research note on Wednesday, August 10th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Aratana Therapeutics presently has a consensus rating of “Buy” and an average target price of $11.00.

Analyst Recommendations for Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics (NASDAQ:PETX) opened at 7.62 on Wednesday. The firm’s 50-day moving average is $8.81 and its 200 day moving average is $7.73. Aratana Therapeutics has a 12 month low of $2.56 and a 12 month high of $10.73. The firm’s market capitalization is $267.40 million.

Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.10. Aratana Therapeutics had a negative net margin of 60.32% and a negative return on equity of 19.87%. During the same quarter last year, the company posted ($1.58) earnings per share. On average, analysts expect that Aratana Therapeutics will post ($0.71) EPS for the current fiscal year.

In other Aratana Therapeutics news, insider Craig A. Tooman sold 30,000 shares of the firm’s stock in a transaction on Friday, September 9th. The shares were sold at an average price of $9.25, for a total value of $277,500.00. Following the completion of the transaction, the insider now directly owns 72,424 shares of the company’s stock, valued at approximately $669,922. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Ernst Heinen sold 10,000 shares of the firm’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $10.00, for a total transaction of $100,000.00. Following the completion of the transaction, the insider now directly owns 115,494 shares of the company’s stock, valued at $1,154,940. The disclosure for this sale can be found here. 6.70% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in PETX. BlackRock Fund Advisors increased its position in shares of Aratana Therapeutics by 6.2% in the third quarter. BlackRock Fund Advisors now owns 1,389,403 shares of the biopharmaceutical company’s stock valued at $13,005,000 after buying an additional 80,724 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Aratana Therapeutics by 20.4% in the second quarter. Vanguard Group Inc. now owns 1,270,655 shares of the biopharmaceutical company’s stock valued at $8,031,000 after buying an additional 214,900 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of Aratana Therapeutics during the third quarter valued at approximately $11,259,000. Massachusetts Financial Services Co. MA increased its position in shares of Aratana Therapeutics by 5.1% in the second quarter. Massachusetts Financial Services Co. MA now owns 971,935 shares of the biopharmaceutical company’s stock valued at $6,143,000 after buying an additional 47,102 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. increased its position in shares of Aratana Therapeutics by 3.1% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 896,521 shares of the biopharmaceutical company’s stock valued at $8,391,000 after buying an additional 27,005 shares during the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

5 Day Chart for NASDAQ:PETX

Receive News & Stock Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related stocks with our FREE daily email newsletter.